Shares shifted sharply higher as Goldman Sachs disclosed it had quietly added to its position in Sellas Life Sciences just as the company's make-or-break cancer trial teeters on the edge of completion. SLS jumped 8.9% to $14.27 on August 19, capping a 29% climb from $11.04 in barely nine trading sessions — a run fueled by institutional buying and a buoyant biotech sector, with the XBI biotech index up 3.73% on the day.

• Goldman Is Buying, But the Bet Is Still Modest

Goldman increased its Sellas stake by 29,122 shares, or 5.2%, to 585,035 shares valued at $8.64 million. That sounds noteworthy, but context matters: Goldman disclosed nearly $75 million in combined holdings across three biotech firms approaching major catalysts , making the Sellas slice the smallest of the three. Susquehanna increased its holding more than fivefold to 2.05 million shares, while Jefferies, Bank of America, and Wellington Management also added to their stakes — a broader institutional wave, not a one-firm conviction call.

• The Trial Is Two Patient Deaths Away From a Verdict

The REGAL study has recorded 78 of the 80 events (patient deaths) required to trigger its final analysis.

Sellas will announce when the 80th event occurs, which will trigger database lock, blinded data review, statistical analysis, unblinding, and disclosure of topline results.

The trial would be deemed successful if the experimental vaccine extends median overall survival to 12.6 months, compared with eight months for standard treatment.

For leukemia patients at this stage, median expected survival with standard care is less than a year.

• A $138 Million Cash Cushion Buys Time Either Way

Sellas reported $138.3 million in cash as of June 30, 2026 , enough to fund operations for years regardless of the trial outcome. Institutional ownership has doubled to 36.34% , a sign the shareholder base has matured from retail-heavy speculation toward more durable holders — though that won't cushion the stock if the data disappoint.

• The Binary Risk Hasn't Changed

The trial passed an interim futility and safety review in January 2025, demonstrating "potential efficacy" and meriting continuation — encouraging, but far from proof. Sellas remains a pre-revenue company whose entire valuation hinges on a single survival readout that could arrive within weeks. Goldman's incremental purchase signals interest, not certainty. Investors buying here are making a calculated wager that the data will clear a bar no one outside the trial can yet see.